Barclays PLC Increases Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Barclays PLC lifted its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 187.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 219,331 shares of the biotechnology company’s stock after purchasing an additional 143,072 shares during the period. Barclays PLC owned about 0.15% of Aurinia Pharmaceuticals worth $1,607,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. FMR LLC raised its stake in Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 3,919 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Aurinia Pharmaceuticals by 10.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the biotechnology company’s stock valued at $301,000 after acquiring an additional 4,808 shares during the last quarter. Handelsbanken Fonder AB raised its position in shares of Aurinia Pharmaceuticals by 13.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 60,700 shares of the biotechnology company’s stock worth $445,000 after acquiring an additional 7,100 shares in the last quarter. PFG Investments LLC lifted its stake in Aurinia Pharmaceuticals by 37.9% during the second quarter. PFG Investments LLC now owns 28,750 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 7,900 shares during the last quarter. Finally, CWM LLC boosted its holdings in Aurinia Pharmaceuticals by 247.7% in the third quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 8,180 shares in the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Jeffrey Allen Bailey sold 4,557 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $8.43, for a total value of $38,415.51. Following the transaction, the director now directly owns 13,356 shares in the company, valued at approximately $112,591.08. This trade represents a 25.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.30% of the stock is owned by insiders.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ AUPH opened at $8.07 on Friday. The stock has a market cap of $1.16 billion, a P/E ratio of -53.80 and a beta of 1.24. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.67. The stock has a 50 day moving average of $8.74 and a two-hundred day moving average of $7.23. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $10.00 price objective on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. StockNews.com raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Aurinia Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.